You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.195.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 09:46, 11 January 2025.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:55, 18 August 2022
- Expiry of block: 13:55, 18 January 2025
Your current IP address is 44.195.68.6. The blocked range is 44.195.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((short description|Case in which having two different versions of a gene provides an advantage))
((more citations needed|date=September 2017))
((Tootechnical|date=August 2022))
A '''heterozygote advantage''' describes the case in which the [[heterozygous]] [[genotype]] has a higher relative [[fitness (biology)|fitness]] than either the [[homozygous]] [[Dominance (genetics)|dominant]] or homozygous [[recessive gene|recessive]] genotype. Loci exhibiting heterozygote advantage are a small minority of loci.<ref>((Cite journal |last=Hedrick |first=Philip W. |date=2012-12-01 |title=What is the evidence for heterozygote advantage selection? |url=https://www.cell.com/trends/ecology-evolution/abstract/S0169-5347(12)00207-8 |journal=Trends in Ecology & Evolution |language=English |volume=27 |issue=12 |pages=698–704 |doi=10.1016/j.tree.2012.08.012 |issn=0169-5347 |pmid=22975220))</ref> The specific case of heterozygote advantage due to a single [[locus (genetics)|locus]] is known as [[overdominance]].<ref>((cite journal |vauthors=Charlesworth D, Willis JH |title=The genetics of inbreeding depression |journal=Nat. Rev. Genet. |volume=10 |issue=11 |pages=783–96 |date=November 2009 |pmid=19834483 |doi=10.1038/nrg2664 |s2cid=771357 ))</ref><ref name=Carr>((cite journal |vauthors=Carr DE, Dudash MR |title=Recent approaches into the genetic basis of inbreeding depression in plants |journal=Philos. Trans. R. Soc. Lond. B Biol. Sci. |volume=358 |issue=1434 |pages=1071–84 |date=June 2003 |pmid=12831473 |pmc=1693197 |doi=10.1098/rstb.2003.1295 ))</ref> Overdominance is a rare<ref>((Cite journal |last1=Charlesworth |first1=Deborah |last2=Willis |first2=John H. |date=November 2009 |title=The genetics of inbreeding depression |url=https://www.nature.com/articles/nrg2664 |journal=Nature Reviews Genetics |language=en |volume=10 |issue=11 |pages=783–796 |doi=10.1038/nrg2664 |pmid=19834483 |s2cid=771357 |issn=1471-0064))</ref> condition in genetics where the [[phenotype]] of the heterozygote lies outside of the phenotypical range of both homozygote parents, and heterozygous individuals have a higher [[fitness (biology)|fitness]] than homozygous individuals.

[[Polymorphism (biology)|Polymorphism]] can be maintained by [[Natural selection|selection]] favoring the heterozygote, and this mechanism is used to explain the occurrence of some kinds of [[genetic variation|genetic variability]]. A common example is the case where the heterozygote conveys both advantages and disadvantages, while both homozygotes convey a disadvantage. A well-established case of heterozygote advantage is that of the gene involved in [[sickle-cell disease|sickle cell anaemia]].

Often, the advantages and disadvantages conveyed are rather complicated, because more than one gene may influence a given [[Phenotypic trait|trait]] or [[Polymorphism (biology)|morph]]. Major [[gene]]s almost always have multiple effects ([[Pleiotropy|pleiotropism]]), which can simultaneously convey separate advantageous traits and disadvantageous traits upon the same organism. In this instance, the state of the organism's environment will provide [[Selection (biology)|selection]], with a net effect either favoring or working in opposition to the gene, until an environmentally determined equilibrium is reached.

Heterozygote advantage is a major underlying mechanism for [[heterosis]], or "hybrid vigor", which is the improved or increased function of any biological quality in a hybrid offspring. Previous research, comparing measures of dominance, overdominance and epistasis (mostly in plants), found that the majority of cases of heterozygote advantage were due to complementation (or dominance), the masking of deleterious recessive alleles by wild-type alleles, as discussed in the articles [[Heterosis]] and [[Complementation (genetics)]], but there were also findings of overdominance, especially in rice.<ref name=Carr />  More recent research, however, has established that there is also an [[Epigenetics|epigenetic]] contribution to heterozygote advantage, primarily as determined in plants,<ref>((cite journal |author=Chen ZJ |title=Molecular mechanisms of polyploidy and hybrid vigor |journal=Trends Plant Sci. |volume=15 |issue=2 |pages=57–71 |date=February 2010 |pmid=20080432 |pmc=2821985 |doi=10.1016/j.tplants.2009.12.003 ))</ref><ref>((cite journal |vauthors=Baranwal VK, Mikkilineni V, Zehr UB, Tyagi AK, Kapoor S |title=Heterosis: emerging ideas about hybrid vigour |journal=J. Exp. Bot. |volume=63 |issue=18 |pages=6309–14 |date=November 2012 |pmid=23095992 |doi=10.1093/jxb/ers291 |doi-access=free ))</ref> though also reported in mice.<ref>((cite journal |vauthors=Han Z, Mtango NR, Patel BG, Sapienza C, Latham KE |title=Hybrid vigor and transgenerational epigenetic effects on early mouse embryo phenotype |journal=Biol. Reprod. |volume=79 |issue=4 |pages=638–48 |date=October 2008 |pmid=18562704 |pmc=2844494 |doi=10.1095/biolreprod.108.069096 ))</ref>

== In theory ==
When two populations of any sexual organism are separated and kept isolated from each other, the frequencies of deleterious mutations in the two populations will differ over time, by [[genetic drift]]. It is highly unlikely, however, that the same deleterious mutations will be common in both populations after a long period of separation. Since loss-of-function mutations tend to be recessive (given that dominant mutations of this type generally prevent the organism from reproducing and thereby passing the gene on to the next generation), the result of any cross between the two populations will be [[Fitness (biology)|fitter]] than the parent.

This article deals with the specific case of fitness [[overdominance]], where the fitness advantage of the cross is caused by being heterozygous at '''one specific''' locus alone.

== Experimental confirmation ==
Cases of both homozygote and heterozygote advantage have been demonstrated in several organisms, including humans.<ref>((Cite journal |last1=Ipsilandis |first1=C. G. |last2=Tokatlidis |first2=I. S. |last3=Vafias |first3=B. |last4=Stefanis |first4=D. |date=2006 |title=Criteria for Developing Second-cycle Hybrids in Maize |url=http://docsdrive.com/pdfs/ansinet/ajps/2006/680-685.pdf |journal=Asian Journal of Plant Sciences |issn=1812-5697))</ref><ref>((Cite journal |last1=Gillespie |first1=Rosemary G |last2=Roderick |first2=George K |date=February 2000 |title=Endless Forms – Species and Speciation |url=http://dx.doi.org/10.1046/j.1365-2540.2000.0704b.x |journal=Heredity |volume=84 |issue=2 |pages=269–270 |doi=10.1046/j.1365-2540.2000.0704b.x |s2cid=36932749 |issn=0018-067X))</ref> The first experimental confirmation of heterozygote advantage was with ''[[Drosophila melanogaster]]'', a fruit fly that has been a [[model organism]] for genetic research. In a classic study on the ebony mutation, Kalmus demonstrated how [[polymorphism (biology)|polymorphism]] can persist in a population through heterozygote advantage.<ref>(( cite journal| author=Kalmus, H.| year=1945 |title=Adaptive and selective responses of a population of Drosophila melanogaster containing e and e+ to differences in temperature, humidity, and to selection for development speed |journal=Journal of Genetics | volume=47 |pages=58–63| doi=10.1007/BF02989038 | s2cid=27175926 ))</ref>

If weakness were the only effect of the mutant allele, so it conveyed only disadvantages, natural selection would weed out this version of the gene until it became extinct from the population. However, the same mutation also conveyed advantages, providing improved viability for heterozygous individuals. The heterozygote expressed none of the disadvantages of homozygotes, yet gained improved viability. The homozygote [[wild type]] was perfectly healthy, but did not possess the improved viability of the heterozygote, and was thus at a disadvantage compared to the heterozygote in survival and reproduction.

This mutation, which at first glance appeared to be harmful, conferred enough of an advantage to heterozygotes to make it beneficial, so that it remained at dynamic equilibrium in the gene pool. Kalmus introduced flies with the ebony mutation to a wild-type population. The ebony allele persisted through many generations of flies in the study, at genotype frequencies that varied from 8% to 30%. In experimental populations, the ebony allele was more prevalent and therefore advantageous when flies were raised at low, dry temperatures, but less so in warm, moist environments.

[[Underdominance|Heterozygote disadvantage]] occurs when "a heterozygote has a lower overall fitness than either homozygote."<ref>((Cite journal |last1=Morris |first1=Brian J. |last2=Chen |first2=Randi |last3=Donlon |first3=Timothy A. |last4=Masaki |first4=Kamal H. |last5=Willcox |first5=D. Craig |last6=Allsopp |first6=Richard C. |last7=Willcox |first7=Bradley J. |date=2021-03-19 |title=Lifespan extension conferred by mitogen-activated protein kinase kinase kinase 5 (MAP3K5) longevity-associated gene variation is confined to at-risk men with a cardiometabolic disease |url=https://www.aging-us.com/article/202844/text |journal=Aging |volume=13 |issue=6 |pages=7953–7974 |doi=10.18632/aging.202844 |issn=1945-4589 |pmc=8034933 |pmid=33739303))</ref> Heterozygote disadvantage occurs in mammals, birds, and insects.<ref>((Cite journal |last1=Nouvellet |first1=P. |last2=Gourbière |first2=S. |date=August 2013 |title=Biased sex-ratio and sex-biased heterozygote disadvantage affect the maintenance of a genetic polymorphism and the properties of hybrid zones |journal=Journal of Evolutionary Biology |language=en |volume=26 |issue=8 |pages=1774–1783 |doi=10.1111/jeb.12180|pmid=23837902 |s2cid=29634107 |doi-access=free ))</ref>

== In human genetics ==

===Sickle-cell anemia===
[[sickle-cell disease|Sickle-cell anemia]] (SCA) is a [[genetic disorder]] caused by the presence of two incompletely recessive alleles. When a sufferer's [[red blood cell]]s are exposed to low-[[oxygen]] conditions, the cells lose their healthy round shape and become sickle-shaped. This deformation of the cells can cause them to become lodged in capillaries, depriving other parts of the body of sufficient oxygen. When untreated, a person with SCA may suffer from painful periodic bouts, often causing damage to [[internal organs]], [[stroke]]s, or [[anemia]].  Typically, the disease results in premature death.

[[File:Sickle Cell Anemia and its Protection Against Malaria.svg|thumb|Possible advantage of being heterozygous for sickle cell anemia disease (A) vs. normal blood cell response (B) when infected with malaria.]]

Because the genetic disorder is incompletely recessive, a person with only one SCA allele and one unaffected allele will have a "mixed" [[phenotype]]: The sufferer will not experience the ill effects of the disease, yet will still possess a [[sickle cell trait]], whereby some of the red blood cells undergo benign effects of SCA, but nothing severe enough to be harmful.  Those afflicted with sickle-cell trait are also known as carriers: If two carriers have a child, there is a 25% chance their child will have SCA, a 50% chance their child will be a carrier, and a 25% chance that the child will neither have SCA nor be a carrier. Were the presence of the SCA allele to confer only negative traits, its allele frequency would be expected to decrease generation after generation, until its presence were eliminated by selection and by chance.

However, convincing evidence indicates, in areas with persistent [[malaria]] outbreaks, individuals with the heterozygous state have a distinct advantage (and this is why individuals with heterozygous alleles are far more common in these areas).<ref>((cite web|author=Bridges, Kenneth |title=Malaria and the Sickle Hemoglobin Gene |date=2 April 2002 |work=Information Center for Sickle Cell and Thalassemic Disorders |url=http://sickle.bwh.harvard.edu/malaria_sickle.html |url-status=dead |archive-url=https://web.archive.org/web/20111127201806/http://sickle.bwh.harvard.edu/malaria_sickle.html |archive-date=27 November 2011 ))</ref><ref>((cite journal |last1=Bunn |first1=H. Franklin|title=The triumph of good over evil: protection by the sickle cell gene against malaria |journal=Blood |date=November 1, 2012 |volume=10 |issue=1182 |pages=20–24 ))</ref> Those with the benign sickle trait possess a resistance to malarial infection. The pathogen that causes the disease spends part of its cycle in the red blood cells and triggers an abnormal drop in oxygen levels in the cell. In carriers, this drop is sufficient to trigger the full sickle-cell reaction, which leads to infected cells being rapidly removed from circulation and strongly limiting the infection's progress. These individuals have a great resistance to infection and have a greater chance of surviving outbreaks. However, those with two alleles for SCA may survive malaria, but will typically die from their genetic disease unless they have access to advanced medical care. Those of the homozygous "normal" or wild-type case will have a greater chance of passing on their genes successfully, in that there is no chance of their offspring's suffering from SCA; yet, they are more susceptible to dying from malarial infection before they have a chance to pass on their genes.

This resistance to infection is the main reason the SCA allele and SCA disease still exist. It is found in greatest frequency in populations where malaria was and often still is a serious problem. Approximately one in 10 African Americans is a carrier,<ref>((cite journal |author1=Lazarin G. A. |author2=Haque I. S. |author3=Nazareth S. |author4=Iori K. |author5=Patterson A. S. |author6=Jacobson J. L. |author7=Marshall J. R. |author8=Seltzer W. K. |author9=Patrizio P. |author10=Evans E. A. |author11=Srinivasan B. S. |date=2013 |title=An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals |journal=Genet. Med. |volume=15 |issue=3 |pages=178–186 |doi=10.1038/gim.2012.114 |pmc=3908551 |pmid=22975760))</ref> as their recent ancestry is from malaria-stricken regions. Other populations in Africa, India, the Mediterranean and the Middle East have higher allele frequencies, as well. As effective antimalarial treatment becomes increasingly available to malaria-stricken populations, the allele frequency for SCA is expected to decrease, so long as SCA treatments are unavailable or only partially effective. If effective sickle-cell anemia treatments become available to the same degree, allele frequencies should remain at their present levels in these populations. In this context, 'treatment effectiveness' refers to the reproductive fitness it grants, rather than the degree of suffering alleviation.

===Cystic fibrosis===

[[Cystic fibrosis]] (CF) is an autosomal recessive hereditary monogenic disease of the [[lungs]], [[sweat gland]]s and [[digestive system]]. The disorder is caused by the malfunction of the [[Cystic fibrosis transmembrane conductance regulator|CFTR]] protein, which controls inter[[membrane transport]] of [[chloride]] ions, which is vital to maintaining equilibrium of water in the body. The malfunctioning protein causes viscous mucus to form in the lungs and intestinal tract. Before modern times, children born with CF would have a life expectancy of only a few years, but modern medicine has made it possible for these people to live into adulthood. However, even in these individuals, CF typically causes male [[infertility]]. It is the most common genetic disease among people of [[European ethnic groups|European]] descent.

The presence of a single CF mutation may influence survival of people affected by diseases involving loss of body fluid, typically due to diarrhea. The most common of these maladies is [[cholera]], which only began killing Europeans millennia after the CF mutation frequency was already established in the population. Another such disease that CF may protect against is [[typhoid]].<ref>((cite journal |last1=Josefson |first1=Deborah |title=CF Gene May Protect against Typhoid Fever |journal=British Medical Journal |date=May 16, 1998 |volume=316 |issue=7143 |page=1481|doi=10.1136/bmj.316.7143.1477j |pmid=9616022 |s2cid=27062771 ))</ref> Those with cholera would often die of dehydration due to intestinal water losses. A mouse model of CF was used to study resistance to cholera, and the results were published in ''Science'' in 1994 (Gabriel, et al.). The heterozygote (carrier) mouse had less secretory diarrhea than normal, noncarrier mice. Thus, it appeared for a time that resistance to cholera explained the selective advantage to being a carrier for CF and why the carrier state was so frequent.

This theory has been called into question. Hogenauer, et al.<ref>((cite journal |vauthors=Högenauer C, Santa Ana CA, Porter JL, etal |title=Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion |journal=Am. J. Hum. Genet. |volume=67 |issue=6 |pages=1422–7 |date=December 2000 |pmid=11055897 |pmc=1287919 |doi=10.1086/316911 ))</ref> have challenged this popular theory with a human study. Prior data were based solely on mouse experiments. These authors found the heterozygote state was indistinguishable from the noncarrier state.

Another theory for the prevalence of the CF mutation is that it provides resistance to [[tuberculosis]]. Tuberculosis was responsible for 20% of all European deaths between 1600 and 1900, so even partial protection against the disease could account for the current gene frequency.<ref>((cite web | last=MacKenzie | first=Debora | title=Cystic fibrosis gene protects against tuberculosis | publisher=New Scientist | url=https://www.newscientist.com/article/dn10013-cystic-fibrosis-gene-protects-against-tuberculosis.html | date=  2006-09-07))</ref>

The most recent hypothesis, published in the Journal of Theoretical Biology, proposed having a single CF mutation granted respiratory advantage for early Europeans migrating north into the dusty wasteland left by the [[Last Glacial Maximum]].<ref>((cite journal | title=Hypothesis: Possible respiratory advantages for heterozygote carriers of cystic fibrosis linked mutations during dusty climate of last glaciation.  | pmid=25150458 | doi=10.1016/j.jtbi.2014.08.015 | volume=363 | journal=J Theor Biol | pages=164–168 | vauthors=Borzan V, Tomašević B, Kurbel S| year=2014 | bibcode=2014JThBi.363..164B ))</ref>

As of 2016, the selective pressure for the high gene prevalence of CF mutations is still uncertain, and may be due to an unbiased genetic drift rather than a selective advantage. Approximately one in 25 persons of European descent is a carrier of the disease, and one in 2500 to 3000 children born is affected by Cystic fibrosis.

===Triosephosphate isomerase===

[[Triosephosphate isomerase]] (TPI) is a central enzyme of [[glycolysis]], the main pathway for cells to obtain energy by metabolizing [[sugar]]s. In humans, certain mutations within this [[enzyme]], which affect the dimerisation of this protein, are causal for a rare disease, [[triosephosphate isomerase deficiency]]. Other mutations, which inactivate the enzyme (= [[null allele]]s) are lethal when inherited [[Zygosity|homozygous]]ly (two defective copies of the TPI gene), but have no obvious effect in [[Zygosity|heterozygotes]] (one defective and one normal copy). However, the frequency of heterozygous null alleles is much higher than expected, indicating a heterozygous advantage for TPI null alleles. The reason is unknown; however, new scientific results are suggesting cells having reduced TPI activity are more resistant against [[oxidative stress]]. [https://dx.doi.org/10.1371/journal.pone.0000030 PlosOne, December  2006]

===Resistance to hepatitis C virus infection===

There is evidence that genetic heterozygosity in humans provides increased resistance to certain viral infections. A significantly lower proportion of HLA-DRB1 heterozygosity exists among HCV-infected cases than uninfected cases. The differences were more pronounced with alleles represented as functional supertypes (P = 1.05 × 10<sup>−6</sup>) than those represented as low-resolution genotypes (P = 1.99 × 10<sup>−3</sup>). These findings constitute evidence that heterozygosity provides an advantage among carriers of different supertype HLA-DRB1 alleles against HCV infection progression to end-stage liver disease in a large-scale, long-term study population.<ref>((cite journal |vauthors=Hraber P, Kuiken C, Yusim K |title=Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection |journal=Hepatology |volume=46 |issue=6 |pages=1713–21 |date=December 2007 |pmid=17935228 |doi=10.1002/hep.21889 |doi-access=free ))</ref>

=== MHC heterozygosity and human scent preferences ===
Multiple studies have shown, in double-blind experiments, females prefer the scent of males who are heterozygous at all three [[Major histocompatibility complex|MHC]] loci.<ref>((cite journal |vauthors=Rikowski A, Grammer K |title=Human body odour, symmetry and attractiveness |journal=Proc. Biol. Sci. |volume=266 |issue=1422 |pages=869–74 |date=May 1999 |pmid=10380676 |pmc=1689917 |doi=10.1098/rspb.1999.0717))</ref><ref>((cite journal |vauthors=Thornhill R, Gangestad S, Miller R, Scheyd G, McCollough J, Franklin M |title=Major histocompatibility complex genes, symmetry, and body scent attractiveness in men and women |journal=Behavioral Ecology |volume=14 |issue=5 |pages=668–678 |date=March–April 2013 |doi=10.1093/beheco/arg043 |doi-access=free ))</ref> The reasons proposed for these findings are speculative; however, it has been argued that heterozygosity at MHC loci results in more alleles to fight against a wider variety of diseases, possibly increasing survival rates against a wider range of infectious diseases.<ref>((cite book |first=David M. |last=Buss |title=The Handbook of Evolutionary Psychology |url=https://books.google.com/books?id=esDW3xTKoLIC |year=2005 |publisher=John Wiley & Sons |isbn=978-0-471-72722-4 |page=357))</ref> The latter claim has been tested in an experiment, which showed outbreeding mice to exhibit MHC heterozygosity enhanced their health and survival rates against multiple-strain infections.<ref>((cite journal |vauthors=Penn DJ, Damjanovich K, Potts WK |title=MHC heterozygosity confers a selective advantage against multiple-strain infections |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=376 |issue=17 |pages=11260–4 |date=August 2002 |pmid=12177415 |pmc=123244 |doi=10.1073/pnas.162006499 |bibcode=2002PNAS...9911260P |doi-access=free ))</ref>

===BAFF and autoimmune disease===
[[B-cell activating factor]] (BAFF) is a cytokine encoded by the TNFSF13B gene. A variant of the gene containing a deletion (GCTGT—>A) renders a shorter mRNA transcript that escapes degradation by [[microRNA]], thus increasing expression of BAFF, which consequently up-regulates the humoral immune response. This variant is associated with [[systemic lupus erythematosus]] and [[multiple sclerosis]], but heterozygote carriers of the variant have decreased susceptibility to malaria infection.<ref>((cite journal |vauthors=Steri M et al. |title=Overexpression of the Cytokine BAFF and Autoimmunity Risk |journal=New England Journal of Medicine |volume=46 |issue=17 |pages=1615–26 |date=April 2017 |pmid=28445677 |pmc=5605835 |doi=10.1056/NEJMoa1610528 ))</ref>

=== Cardiometabolic disease ===
Variants of the kinase-related [[MAP3K5]] are associated with lifespan. In a study among Japanese-Americans, homozygous individuals have a longer lifespan than heterozygous individuals, indicating a homozygote advantage.

==See also==
* [[Balanced polymorphism]]
* [[Hybrid vigour]]
* [[Miscegenation]]
* [[Overdominance]]
* [[Polymorphism (biology)]]

==Notes==
((reflist))

((DEFAULTSORT:Heterozygote Advantage))
[[Category:Population genetics]]
[[Category:Selection]]

Pages transcluded onto the current version of this page (help):

Heterozygote advantage (edit)
Template:Ambox (view source) (template editor protected)
Template:Cite book (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Cite web (view source) (protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Technical (view source) (template editor protected)
Template:Tootechnical (edit)
Module:Arguments (view source) (protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Disambiguation/templates (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:SDcat (view source) (protected)
Module:String (view source) (protected)
Module:Unsubst (view source) (protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to Heterozygote advantage.

Retrieved from "https://en.wikipedia.org/wiki/Heterozygote_advantage"